The Living Guidelines: Ancillary Therapy for Patients Undergoing PCI for STEMI View the Current CLASS I Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class I Guidelines

 * 1) For patients undergoing PCI after having received an anticoagulant regimen, the following dosing recommendations should be followed:
 * a. For prior treatment with UFH, administer additional boluses of UFH as needed to support the procedure, taking into account whether GP IIb/IIIa receptor antagonists have been administered. (Class I Level of Evidence: C) Bivalirudin may also be used in patients treated previously with UFH. (Class I Level of Evidence: C)


 * b. For prior treatment with enoxaparin, if the last subcutaneous dose was administered at least 8 to 12 hours earlier, an IV dose of 0.3 mg/kg of enoxaparin should be given; if the last subcutaneous dose was administered within the prior 8 hours, no additional enoxaparin should be given. (Class I Level of Evidence: B)


 * c. For prior treatment with fondaparinux, administer additional intravenous treatment with an anticoagulant possessing anti-IIa activity, taking into account whether GP IIb/IIIa receptor antagonists have been administered. (Class I Level of Evidence: C)